Eagle Pharmaceuticals focuses on the discovery, development, and marketing of innovative medicines that address significant healthcare needs. The company emphasizes a commitment to enhancing patient care through its product portfolio, which includes first-in-class new chemical entities (NCEs) aimed at treating conditions in oncology and critical care. Their flagship products, such as BARHEMSYS® and BYFAVO®, utilize advanced pharmacological mechanisms to provide effective solutions for postoperative nausea and vomiting (PONV) and procedural sedation, respectively. BARHEMSYS® acts as a selective dopamine receptor antagonist, while BYFAVO® is a benzodiazepine designed for rapid sedation, showcasing Eagle's dedication to leveraging science and technology to improve patient outcomes.

The company’s pipeline reflects a strategic focus on developing therapies that not only meet clinical needs but also create value for patients and healthcare systems. Eagle Pharmaceuticals is committed to rigorous research and development processes, ensuring that their products are backed by clinical evidence and safety data. This commitment is evident in their approach to addressing potential adverse reactions and contraindications associated with their medications, as well as their ongoing efforts to monitor and enhance the efficacy of their treatments. Through these initiatives, Eagle Pharmaceuticals aims to make a meaningful impact on healthcare and the lives of patients.

United States

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and Byfavo® and Barhemsys® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com. 


Age-related diseases

Cancer

Central Nervous System (CNS)

Infectious Diseases

Lung Diseases

Metabolic Diseases

Rare diseases

Eagle Pharmaceuticals

Vasodilary shock

Vasopressin

Malignant hyperthermia

<p class="font_7">The addition of dantrolene to the “triggered” malignant hyperthermic muscle cell may reestablish a normal level of ionized calcium in the myoplasm. Inhibition of calcium release from the sarcoplasmic reticulum by dantrolene reestablishes the myoplasmic calcium equilibrium, increasing the percentage of bound calcium. In this way, physiologic, metabolic, and &nbsp;biochemical changes associated with the malignant hyperthermia crisis may be reversed or attenuated.</p>

Ryanodex (dantrolene sodium) injectable

Chronic lymphocytic leukemia

Dementia

Non-Hodgkin lymphoma

Parkinson's disease

<p class="font_7">Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism of action of bendamustine remains unknown.</p>

Eagle Pharmaceuticals

Company Details